{"id":"atropine-sulfate-03","safety":{"commonSideEffects":[{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Mydriasis and cycloplegia"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Confusion or agitation (at high doses)"},{"rate":null,"effect":"Hyperthermia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atropine competitively antagonizes acetylcholine at muscarinic receptors throughout the body, reducing parasympathetic effects on the heart, smooth muscle, and secretory glands. This results in increased heart rate, bronchodilation, reduced secretions, and mydriasis. The sulfate salt formulation enhances solubility and bioavailability for parenteral or oral administration.","oneSentence":"Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:03.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anticholinergic poisoning and organophosphate/nerve agent exposure"},{"name":"Symptomatic bradycardia and heart block"},{"name":"Mydriasis and cycloplegia for ophthalmic examination"},{"name":"Reduction of salivary, bronchial, and gastric secretions perioperatively"}]},"trialDetails":[{"nctId":"NCT05529056","phase":"PHASE3","title":"Study of Atropine Therapeutic Effect on Myopic Progression","status":"UNKNOWN","sponsor":"LitePharmTech Co., Ltd.","startDate":"2022-05-25","conditions":"Myopia, Children","enrollment":472}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":732,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LPTAT03"],"phase":"phase_3","status":"active","brandName":"Atropine Sulfate 03","genericName":"Atropine Sulfate 03","companyName":"LitePharmTech Co., Ltd.","companyId":"litepharmtech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity. Used for Anticholinergic poisoning and organophosphate/nerve agent exposure, Symptomatic bradycardia and heart block, Mydriasis and cycloplegia for ophthalmic examination.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}